高强度他汀与PD-1抑制剂在恶性胸膜间皮瘤和晚期非小细胞肺癌中临床活性改善相关
本研究回顾性分析82例恶性胸膜间皮瘤(MPM)和179例晚期非小细胞肺癌(aNSCLC)患者,均接受PD-1抑制剂二线或后线治疗,另以77例标准化疗MPM患者为对照。结果显示他汀使用与更高的客观缓解率(ORR)、无进展生存期(PFS)和总生存期(OS)相关,且高强度他汀与更好OS相关,效应呈强度依赖性。
要点
- 他汀使用与PD-1抑制剂治疗MPM和aNSCLC患者ORR、PFS改善相关。
- 高强度他汀与更好OS相关,低/中强度他汀无此关联。
- 化疗对照MPM队列中未发现他汀使用与结局的关联。
核心结论
- 他汀使用与MPM和aNSCLC患者接受PD-1抑制剂治疗后更好的临床结局相关,且呈强度依赖性。
研究设计与样本
- 回顾性分析82例MPM和179例aNSCLC患者,均接受PD-1抑制剂二线或后线治疗;另分析77例标准化疗MPM患者作为对照。
主要发现
- 化疗对照MPM队列(n=77)中未发现他汀使用与结局的关联。
临床怎么用
- 在接受PD-1抑制剂治疗的MPM和aNSCLC患者中,他汀使用(尤其高强度他汀)可能与更好的疗效相关,但需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In preclinical models, statins showed vaccine adjuvant activities and synergized with PD-1 inhibitors. We analyzed the impact of statin treatment on clinical outcome in thoracic cancer patients treated with PD-1 inhibitors. METHODS: A total of 82 malignant pleural mesothelioma (MPM) and 179 advanced non-small cell lung cancer (aNSCLC) patients treated with PD-1 inhibitors as second or further line treatment were examined. Seventy-seven MPM patients treated with standard chemotherapy were analyzed as control cohort. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were calculated. RESULTS: Among 253 patients with available data, statin use was associated with increased ORR (32% versus 18%, P = .02), PFS (median 6.7 versus 2.9 months, hazard ratio [HR] 0.57, 95% CI 0.39-0.83, P < .01), and OS (median 13.1 versus 8.7 months, HR 0.67, 95% CI 0.45-1.00, P = .05). In the control MPM cohort treated with chemotherapy (n = 77), no association was found. MPM patients who used statins showed improved ORR (22% versus 6%, P = .05), PFS (median 6.7 versus 2.4 months, P < .01), and OS (median not reached versus 6.0 months, P = .01). In aNSCLC patients, statin use was associated with improved ORR (40% versus 22%, P = .04) and PFS (median 7.8 versus 3.6 months, P = .03), but no significant difference in OS was found (median 13.1 versus 10.1 months, P = .30). Multivariable analysis confirmed the correlation between statin use and better PFS and OS in MPM and better PFS in aNSCLC. In the whole cohort, high but not low/moderate-intensity statins were associated with better OS compared to no user (P = .02 and P = .59, respectively). CONCLUSIONS: Our study showed that statins are associated with better clinical outcome in MPM and aNSCLC patients treated with PD-1 inhibitors in an intensity-dependent manner.
引用
- Cantini L, Pecci F, Hurkmans DP, et al. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. Eur J Cancer. 2020. PMID: 33326868. doi:10.1016/j.ejca.2020.10.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。